The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...
It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
The National Numismatic Collection is comprised of approximately 1.6 million objects and is thought to be the largest collection of money and transactional objects in the world. Its diverse holdings ...
Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results